The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology



Status:Recruiting
Conditions:Gastrointestinal, Gastrointestinal
Therapuetic Areas:Gastroenterology
Healthy:No
Age Range:18 - 70
Updated:1/28/2018
Start Date:December 8, 2017
End Date:May 2022
Contact:Andrea Herman, RN, BA
Email:andrea.herman@hepquant.com
Phone:303-923-2210

Use our guide to learn which trials are right for you!

The HepQuant SHUNT test, which is provided as a HepQuant SHUNT Liver Diagnostic Kit, is a
minimally-invasive test of liver function and physiology which has been designated by the FDA
as an investigational drug/device combination product.

Enrollment into one of the 3 Gilead Selonsertib clinical trials (GS-US-416-2124,
GS-US-384-1943/1944) is required for enrollment into the HepQuant study

The HepQuant study is to run parallel to the Gilead clinical trials,GS-US-416-2124 trial of
Alcoholic Hepatitis, GS-US-384-1943 trial of non-alcoholic steatohepatitis (NASH) fibrosis
Stage 3 (STELLAR-3), and, GS-US-384-1944 trial of NASH and compensated cirrhosis (STELLAR-4).
The time points for the HepQuant SHUNT tests coincide with pre-specified time points within
the Gilead clinical trials. Subjects enrolled in GILEAD's STELLAR and Alcoholic hepatitis
trials may participate concurrently in this HepQuant sponsored investigational device study
at participating US sites only (IDEs as listed above) once approved by the applicable
IRB/IEC.

The main eligibility criteria for enrollment into the HepQuant study is enrollment into one
of the three Gilead clinical trials listed above.

The HepQuant SHUNT Test is minimally-invasive and measures hepatocyte function and inflow to
the liver from the simultaneous clearances (hepatic filtration rates, HFRs) of cholate from
systemic and portal circulations. The Test quantifies portal-systemic shunting (SHUNT) and
generates a liver disease severity index (DSI). DSI is a score from 0 (no disease) to 50
(terminal illness) that is a composite of both HFRs and correlates with stage of fibrosis,
presence of varices, especially large varices, and risk for future clinical outcomes. DSI is
the primary output variable from the HepQuant SHUNT test. The HepQuant SHUNT test potentially
satisfies the unmet medical need for a minimally-invasive test of global liver function and
physiology

Inclusion Criteria:

The key inclusion criteria for this HepQuant Parallel Study are the inclusion criteria into
one of the Gilead selonsertib trials (GS-US-416-2124, GS-US-384-1943 or 1944). Once that
has been met, subjects must:

- Be able to ingest liquid by mouth

- Have venous access to support a peripheral IV and 6 blood draws

Exclusion Criteria:

The key exclusion criteria for this HepQuant Parallel Study are the exclusion criteria for
one of the Gilead selonsertib trials (GS-US-416-2124, GS-US-384-1943 or 1944). If this has
been met, the subject is not eligible to participate in HepQuant. If no exclusion criteria
has been met for the Gilead selonsertib trial, ADDITIONAL exclusions for HepQuant are:

- Subject should not have had first dose of selonsertib

- Subject cannot take anything by mouth

- Subject cannot be hypersensitive to eggs, albumin preparations, any ingredient in the
formulation, or component of the container

- Subject cannot have intercurrent medical or surgical illness (eg: acute MI, acute
cerebral hemorrhage, sepsis)

- subject cannot have had extensive resection of large segments of small intestine
(short gut)

- Subject cannot have severe gastroparesis
We found this trial at
8
sites
Seattle, Washington 98103
Principal Investigator: Kiran Bambha, MD
Phone: 206-543-0826
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Dallas, Texas 75203
Principal Investigator: Parvez Mantry, MD
Phone: 214-947-1288
?
mi
from
Dallas, TX
Click here to add this to my saved trials
505 Nolen Drive
Dallas, Texas 76092
Principal Investigator: James Trotter, MD
Phone: 214-820-1710
?
mi
from
Dallas, TX
Click here to add this to my saved trials
Miami, Florida 33136
Principal Investigator: Kaylan Bhamidimarri, MD
Phone: 305-243-6681
?
mi
from
Miami, FL
Click here to add this to my saved trials
Philadelphia, Pennsylvania 19104
Principal Investigator: Rajender Reddy, MD
Phone: 215-349-8563
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
1201 Broad Rock Boulevard
Richmond, Virginia 23224
Principal Investigator: Michael Fuchs, MD
Phone: 804-675-6407
?
mi
from
Richmond, VA
Click here to add this to my saved trials
Richmond, Virginia 23298
(804) 828-0100
Principal Investigator: Arun Sanyul, MD
Phone: 804-828-6314
Virginia Commonwealth University Since our founding as a medical school in 1838, Virginia Commonwealth University...
?
mi
from
Richmond, VA
Click here to add this to my saved trials
San Antonio, Texas 78215
Principal Investigator: Naim Alkhouri, MD
Phone: 210-253-3426
?
mi
from
San Antonio, TX
Click here to add this to my saved trials